Mothaffar Rimawi

Mothaffar Rimawi has contributed to establishing HER2-low as a clinically meaningful breast cancer subgroup amenable to antibody-drug conjugate therapy in patients with hormone receptor-positive disease. His research characterized the intersection of HER2-low expression, HR+ endocrine signaling, and resistance to both endocrine and anti-HER2 therapies, informing combination strategies. He participated in clinical investigations of trastuzumab deruxtecan in HR+/HER2-low metastatic breast cancer, which established this ADC as a transformative treatment option based on the DESTINY-Breast04 trial results. His translational work on HER2-directed therapy combinations with CDK4/6 inhibitors and endocrine therapy in luminal B and HER2-enriched breast cancers has informed understanding of molecular co-targeting strategies.